ReviewPhysical medicine and rehabilitation clinics of North America2012
Novel approaches to corticosteroid treatment in Duchenne muscular dystrophy.
Review in Physical medicine and rehabilitation clinics of North America, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 65 citations in OpenAlex.
- Impact of biobanks on research outcomes in rare diseases: a systematic review.Orphanet journal of rare diseases · 2018Pooled it
- Guideline
- Muscular response to the first three months of deflazacort treatment in boys with Duchenne muscular dystrophy.Journal of musculoskeletal & neuronal interactions · 2017Trial
- Comparing intermittent and daily prednisone in duchenne muscular dystrophy: a systematic review and meta-analysis.Annals of medicine and surgery (2012) · 2025Article
- Article
- Review
- Comparison of two corticosteroid regimens on brain volumetrics in patients with Duchenne muscular dystrophy.Annals of clinical and translational neurology · 2023Article
- Mechanism of action and therapeutic route for a muscular dystrophy caused by a genetic defect in lipid metabolism.Nature communications · 2022Article
- Macrophages in Skeletal Muscle Dystrophies, An Entangled Partner.Journal of neuromuscular diseases · 2022Review
- Comparing Deflazacort and Prednisone in Duchenne Muscular Dystrophy.Journal of neuromuscular diseases · 2022Review
- Article
- Disruption of a key ligand-H-bond network drives dissociative properties in vamorolone for Duchenne muscular dystrophy treatment.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Dysregulation of Calcium Handling in Duchenne Muscular Dystrophy-Associated Dilated Cardiomyopathy: Mechanisms and Experimental Therapeutic Strategies.Journal of clinical medicine · 2020Review
- Cardiac Pathophysiology and the Future of Cardiac Therapies in Duchenne Muscular Dystrophy.International journal of molecular sciences · 2019Review
- Two-Year Longitudinal Changes in Lower Limb Strength and Its Relation to Loss in Function in a Large Cohort of Patients With Duchenne Muscular Dystrophy.American journal of physical medicine & rehabilitation · 2018Article
- Taurine and Methylprednisolone Administration at Close Proximity to the Onset of Muscle Degeneration Is Ineffective at Attenuating Force Loss in the Hind-Limb of 28 DaysSports (Basel, Switzerland) · 2018Article
- One-year follow up of three Italian patients with Duchenne muscular dystrophy treated with ataluren: is earlier better?Therapeutic advances in neurological disorders · 2018Article
- Glucocorticoids Improve Myogenic Differentiation In Vitro by Suppressing the Synthesis of Versican, a Transitional Matrix Protein Overexpressed in Dystrophic Skeletal Muscles.International journal of molecular sciences · 2017Article
- Recent developments in Duchenne muscular dystrophy: facts and numbers.Journal of cachexia, sarcopenia and muscle · 2017Article
- A multispecies approach for understanding neuroimmune mechanisms of stress.Dialogues in clinical neuroscience · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
Although prednisone has never been formally approved for use in Duchenne muscular dystrophy (DMD) by regulatory agencies, its efficacy has been confirmed in trials dating from the 1980s. There is a strong need for optimization of both specific type of glucocorticoid (eg, prednisone, vs deflazacort or others) and the dosing regimen. Ideally an optimized regimen would maximize efficacy while minimizing side-effect profiles. A new trial, FOR-DMD, aims to address this gap in knowledge. In parallel, there has been progress in the area of "dissociative steroids," drugs that are able to better separate efficacy and side effects, providing a broader therapeutic window.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.